Key result
Protein acetylation impairs cardiac glucose uptake, driving metabolic inflexibility in diabetic cardiomyopathy.
Why the study?
The molecular mechanisms leading to cardiac metabolic inflexibility and impaired insulin-stimulated glucose uptake in type 2 diabetes remain incompletely understood, particularly the role of protein acetylation.
This review highlights the emerging role of protein acetylation as a key molecular mechanism driving metabolic inflexibility and impaired glucose uptake in diabetic cardiomyopathy.
Impaired cardiac metabolic flexibility in T2D may heighten cardiomyopathy risk; leaves open whether targeting substrate switching improves outcomes.
Cellular catabolism is the cell capacity to generate energy from various substrates to sustain its function. To optimize this energy production, cells are able to switch between various metabolic pathways in accordance to substrate availability via a modulation of several regulatory enzymes. This metabolic flexibility is essential for the healthy heart, an organ requiring large quantities of ATP to sustain its contractile function. In type 2 diabetes, excess of non-glucidic nutrients such as fatty acids, branched-chain amino-acids, or ketones bodies, induces cardiac metabolic inflexibility. It is characterized by a preferential use of these alternative substrates to the detriment of glucose, this participating in cardiomyocytes dysfunction and development of diabetic cardiomyopathy. Identification of the molecular mechanisms leading to this metabolic inflexibility have been scrutinized during last decades. In 1963, Randle demonstrated that accumulation of some metabolites from fatty acid metabolism are able to allosterically inhibit regulatory steps of glucose metabolism leading to a preferential use of fatty acids by the heart. Nevertheless, this model does not fully recapitulate observations made in diabetic patients, calling for a more complex model. A new piece of the puzzle emerges from recent evidences gathered from different laboratories showing that metabolism of the non-glucidic substrates induces an increase in acetylation levels of proteins which is concomitant to the perturbation of glucose transport. The purpose of the present review is to gather, in a synthetic model, the different evidences that demonstrate the role of acetylation in the inhibition of the insulin-stimulated glucose uptake in cardiac muscle.
No takes yet. Share an insight, caveat, or question.
Renguet et al. (2018) conducted a review in Diabetic cardiomyopathy and insulin resistance. Protein acetylation was evaluated. Increased protein acetylation driven by non-glucidic substrates diminishes insulin-stimulated cardiac glucose uptake, contributing to metabolic inflexibility in diabetic cardiomyopathy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: